1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Continued ritlecitinib treatment can lead to hair regrowth in some patients with alopecia areata who initially don't respond.
September 2023 in “Journal of the American Academy of Dermatology”
3 citations
,
March 2016 in “Phytotherapy Research” The new compound was more effective than finasteride in reducing markers of hair loss and prostate issues in cell tests.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
March 2024 in “EMBO molecular medicine” Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
Neurosteroids help control dopamine responses in the brain.
March 2026 in “Frontiers in Medicine” High-dose testosterone with finasteride improves muscle health in males with spinal cord injury.
18 citations
,
March 2006 in “Expert Review of Neurotherapeutics” The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
10 citations
,
June 2011 in “Movement Disorders” THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference” February 2023 in “European Journal of Medical Research” Certain existing drugs, like glycopyrronium and botulinum toxin type A, may help treat excessive sweating.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
1 citations
,
November 2010 in “Anticancer Research” Finasteride and dutasteride both increase chromogranin A levels similarly.
4 citations
,
July 2024 in “Pharmacology Research & Perspectives” Ritlecitinib is safe and may effectively treat alopecia areata.
2 citations
,
November 2004 in “Hospital pharmacy” Certain medications can cause serious side effects, so it's important to report them.
May 2023 in “Journal of Drugs in Dermatology” REVIVV® serum improves hair growth and reduces shedding in androgenetic alopecia.
Men with early-onset hair loss are less responsive to bromocriptine's heart and metabolism benefits.
15 citations
,
January 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
May 2008 in “10th European Congress of Endocrinology” 1 citations
,
March 2026 in “American Journal of Clinical Dermatology”
9 citations
,
December 2023 in “Journal of Neuroimmune Pharmacology” NDP-MSH protects brain cells and reduces inflammation in Parkinson's disease by activating MC1R and involving Tregs.
Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.
13 citations
,
February 2013 in “BMJ Case Reports” Stopping finasteride improved seizure control, suggesting neurosteroids affect seizures and treatment.
January 2026 in “Pharmaceutical journal/The pharmaceutical journal” Finasteride and dutasteride now have stronger warnings for psychiatric and sexual side effects.
May 2025 in “Immunotherapy” Patients were very satisfied with hair regrowth after taking ritlecitinib for alopecia areata.